Masimo Co. (NASDAQ:MASI) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 337,221 shares of the medical equipment provider's stock after selling 4,739 shares during the period. Bank of New York Mellon Corp owned 0.63% of Masimo worth $55,743,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its stake in shares of Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 123 shares during the last quarter. Trust Co. of Vermont acquired a new position in shares of Masimo in the 4th quarter valued at $33,000. Blue Trust Inc. lifted its stake in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Masimo by 136.5% in the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider's stock valued at $77,000 after purchasing an additional 269 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Masimo in the 3rd quarter valued at $118,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wells Fargo & Company upped their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Stifel Nicolaus reiterated a "buy" rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Finally, Piper Sandler boosted their price objective on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $194.80.

Remove Ads

Masimo Stock Down 0.6 %

NASDAQ MASI traded down $1.09 during trading hours on Friday, hitting $174.52. 630,748 shares of the company were exchanged, compared to its average volume of 619,971. The company has a 50 day moving average of $174.95 and a two-hundred day moving average of $155.78. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The firm has a market cap of $9.42 billion, a price-to-earnings ratio of 120.36 and a beta of 1.04.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Equities research analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.